CN109206501B - Cat interferon omega, coding gene thereof and application of cat interferon omega in antiviral aspect - Google Patents
Cat interferon omega, coding gene thereof and application of cat interferon omega in antiviral aspect Download PDFInfo
- Publication number
- CN109206501B CN109206501B CN201811125211.2A CN201811125211A CN109206501B CN 109206501 B CN109206501 B CN 109206501B CN 201811125211 A CN201811125211 A CN 201811125211A CN 109206501 B CN109206501 B CN 109206501B
- Authority
- CN
- China
- Prior art keywords
- omega
- feline
- interferon
- cat
- interferon omega
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000282326 Felis catus Species 0.000 title claims abstract description 61
- 108010045648 interferon omega 1 Proteins 0.000 title claims abstract description 60
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 29
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 23
- 241000282324 Felis Species 0.000 claims abstract description 37
- 239000002773 nucleotide Substances 0.000 claims abstract description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000013604 expression vector Substances 0.000 claims description 21
- 238000003259 recombinant expression Methods 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 8
- 229960000723 ampicillin Drugs 0.000 claims description 8
- 238000001261 affinity purification Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 238000001976 enzyme digestion Methods 0.000 claims description 5
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 239000012880 LB liquid culture medium Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 241000701925 Feline parvovirus Species 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 238000007747 plating Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 abstract description 26
- 102000014150 Interferons Human genes 0.000 abstract description 21
- 229940079322 interferon Drugs 0.000 abstract description 20
- 230000000638 stimulation Effects 0.000 abstract description 6
- 238000012408 PCR amplification Methods 0.000 abstract description 5
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 abstract description 4
- 239000002799 interferon inducing agent Substances 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000002155 anti-virotic effect Effects 0.000 abstract description 2
- 239000003443 antiviral agent Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012407 engineering method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710169571 Interferon omega-2 Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- NTUPOKHATNSWCY-PMPSAXMXSA-N (2s)-2-[[(2s)-1-[(2r)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-PMPSAXMXSA-N 0.000 description 1
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 1
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- PXAFZDXYEIIUTF-LKTVYLICSA-N Ala-Trp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O PXAFZDXYEIIUTF-LKTVYLICSA-N 0.000 description 1
- TVUFMYKTYXTRPY-HERUPUMHSA-N Ala-Trp-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O TVUFMYKTYXTRPY-HERUPUMHSA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- ANAHQDPQQBDOBM-UHFFFAOYSA-N Arg-Val-Tyr Natural products CC(C)C(NC(=O)C(N)CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O ANAHQDPQQBDOBM-UHFFFAOYSA-N 0.000 description 1
- GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 description 1
- VFUXXFVCYZPOQG-WDSKDSINSA-N Asp-Glu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VFUXXFVCYZPOQG-WDSKDSINSA-N 0.000 description 1
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 1
- LIJXJYGRSRWLCJ-IHRRRGAJSA-N Asp-Phe-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LIJXJYGRSRWLCJ-IHRRRGAJSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 1
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- MCGNJCNXIMQCMN-DCAQKATOSA-N Glu-Met-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCC(O)=O MCGNJCNXIMQCMN-DCAQKATOSA-N 0.000 description 1
- GVVKYKCOFMMTKZ-WHFBIAKZSA-N Gly-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CN GVVKYKCOFMMTKZ-WHFBIAKZSA-N 0.000 description 1
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- ZUPVLBAXUUGKKN-VHSXEESVSA-N His-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CN=CN2)N)C(=O)O ZUPVLBAXUUGKKN-VHSXEESVSA-N 0.000 description 1
- DQZCEKQPSOBNMJ-NKIYYHGXSA-N His-Thr-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DQZCEKQPSOBNMJ-NKIYYHGXSA-N 0.000 description 1
- AZEYWPUCOYXFOE-CYDGBPFRSA-N Ile-Arg-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)O)N AZEYWPUCOYXFOE-CYDGBPFRSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- VZBIUJURDLFFOE-IHRRRGAJSA-N Leu-His-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VZBIUJURDLFFOE-IHRRRGAJSA-N 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- VLZGUAUYZGQKPM-DRZSPHRISA-N Phe-Gln-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VLZGUAUYZGQKPM-DRZSPHRISA-N 0.000 description 1
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 1
- FEVDNIBDCRKMER-IUCAKERBSA-N Pro-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@@H]1CCCN1 FEVDNIBDCRKMER-IUCAKERBSA-N 0.000 description 1
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 1
- 108010003201 RGH 0205 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- CTRHXXXHUJTTRZ-ZLUOBGJFSA-N Ser-Asp-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O CTRHXXXHUJTTRZ-ZLUOBGJFSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- KEANSLVUGJADPN-LKTVYLICSA-N Tyr-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N KEANSLVUGJADPN-LKTVYLICSA-N 0.000 description 1
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 1
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 108010050343 histidyl-alanyl-glutamine Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108010072637 phenylalanyl-arginyl-phenylalanine Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a cat interferon omega, a coding gene thereof and application thereof in the aspect of antivirus. The amino acid sequence of the cat interferon omega is shown in SEQ ID NO. 2. The nucleotide sequence of the preferred code cat interferon omega is shown in SEQ ID NO. 1. In addition, the invention also discloses a method for preparing the feline interferon omega and application of the feline interferon omega in preparing antiviral drugs. The invention adopts a method of virus stimulation (feline enterocoronavirus) and interferon inducer stimulation (poly I: C) to stimulate pet cats so as to induce the expression of feline interferon genes. Then, a cat interferon omega gene is obtained through PCR amplification, and cell tests show that the cat interferon omega obtained by the invention has obvious antiviral activity and is superior to the existing known cat interferon. The invention lays a foundation for further research and development and application of the cat interferon product.
Description
Technical Field
The invention relates to a novel cat interferon omega, a coding gene thereof and application thereof in the aspect of antivirus. The invention belongs to the technical field of veterinary drugs.
Background
Interferon is an antiviral cytokine produced when the body is infected by virus, is released by infected cells to inhibit the proliferation of virus, and has broad-spectrum antiviral and immune response enhancing effects. There are two broad classes of interferons that have been identified: form I and form II. The type I interferon mainly comprises IFN-alpha, IFN-beta and IFN-omega; the type II interferon is mainly IFN-gamma. At present, the research of human interferon is rapidly progressed, for example, the recombinant human interferon alpha in genetic engineering has been widely used for the treatment of human virus infection, and the recombinant human interferon omega has also been used for the treatment of SARS.
In recent years, the breeding quantity of pet cats in China is rapidly increased, and the pet cats become a part of leisure life of people, and a plurality of virus diseases seriously harm the health and survival of the pet cats. Interferon is the most effective therapeutic drug for treating viral infectious diseases, but the research on cat interferon and the development of clinical preparations are relatively lagged, and the published cat interferon sequence is relatively limited.
The invention discloses a novel cat interferon omega and a coding gene sequence thereof, prepares the novel cat interferon by a gene engineering method and performs antiviral activity determination, and provides a material basis for the research and development of cat interferon biological products.
Disclosure of Invention
The invention aims to provide a novel cat interferon omega and a coding gene thereof.
In order to achieve the purpose, the invention adopts the following technical means:
the invention adopts a method of virus stimulation (feline enterocoronavirus) and interferon inducer stimulation (poly I: C) to stimulate pet cats so as to induce the expression of feline interferon genes. Then, according to a cat interferon omega gene sequence published in GenBank, gene sequence comparison is carried out through DNAMAN, a pair of degenerate primers are designed by using Oligo6 to amplify the cat interferon omega gene, and finally, the invention obtains a novel gene sequence for coding the cat interferon omega, and through sequencing and BLAST comparison, the homology of the gene sequence with the published cat interferon omega gene is higher, the gene sequence belongs to a new member of the cat interferon omega, the nucleotide sequence is shown as SEQ ID NO.1, and the coded amino acid sequence is shown as SEQ ID NO. 2. The novel cat interferon is prepared by a gene engineering method and antiviral activity determination is carried out on the novel cat interferon, and the result shows that the novel cat interferon omega has good antiviral activity, the effective antiviral concentration is 0.70mg/mL, the novel cat interferon omega is superior to the known cat interferon, and good application potential is shown.
On the basis of the research, the invention provides a novel cat interferon omega, and the amino acid sequence of the cat interferon omega is shown as SEQ ID No. 2.
The nucleotide sequence for coding the feline interferon omega, the recombinant expression vector containing the nucleotide sequence and the host cell containing the recombinant expression vector are also within the scope of the invention. Wherein, preferably, the nucleotide sequence is shown as SEQ ID NO. 1.
Furthermore, the invention also provides application of the feline interferon omega in preparation of antiviral drugs.
Preferably, the medicament is used for treating or preventing viral infectious diseases of cats.
Preferably, the virus includes feline enterocoronavirus and feline parvovirus.
Furthermore, the invention also provides a method for preparing the cat interferon omega, which comprises the following steps:
(1) obtaining a nucleotide sequence for coding the cat interferon omega, and connecting Kpn I and BamH I enzyme cutting sites at two ends of the sequence;
(2) construction of recombinant expression vector pCold-TF-omega
Respectively carrying out double enzyme digestion treatment on an expression vector pCold-TF and the sequence obtained in the step (1) by using restriction enzymes Kpn I and BamH I, recovering a target gene fragment by using a DNA gel recovery kit, and further connecting the sequence obtained in the step (1) into the expression vector pCold-TF by using T4 ligase to construct a recombinant expression vector named pCold-TF-omega;
(3) construction of recombinant bacterium pCold-TF-omega/BL 21
Transforming BL21 competent cells by using the recombinant expression vector pCold-TF-omega, coating the competent cells on an LB agar plate containing ampicillin resistance for culture, and selecting a positive recombinant bacterium named pCold-TF-omega/BL 21;
(4) inducible expression
Overnight plating and activating recombinant bacteria pCold-TF-omega/BL 21, selecting a single colony, inoculating the single colony in an LB liquid culture medium containing 100 mu g/ml ampicillin, and performing shake culture at 37 ℃ overnight; transferring the new culture broth into LB liquid culture medium containing ampicillin resistance according to the volume ratio of 1:10, and culturing at 37 deg.C to OD600When the concentration is 0.4-0.6, adding IPTG with the final concentration of 1mmol/L, and inducing for 6h at 37 ℃; and (3) taking the induced recombinant bacterial liquid, centrifuging, discarding the supernatant, adding PBS (phosphate buffer solution) to resuspend the thallus, carrying out ultrasonic treatment, then adding 5 xSDS (sodium dodecyl sulfate) sample lysate, carrying out boiling water bath for 10min, centrifuging, taking the supernatant, carrying out His-tag affinity purification on the recombinant fusion protein, carrying out HRV 3C protease treatment and His-tag affinity purification, and finally obtaining the cat interferon omega.
Wherein, preferably, the nucleotide sequence for coding the feline interferon omega is shown in SEQ ID NO. 1.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention discloses a novel cat interferon omega and a coding gene sequence thereof, and a gene engineering method is used for preparing the cat interferon omega, thereby meeting the requirement on cat interferon in the market.
2. Cell tests show that the novel cat interferon omega disclosed by the invention has obvious antiviral activity and is superior to the existing known cat interferon. The invention lays a foundation for further research and development and application of the cat interferon product.
Drawings
FIG. 1 shows the result of PCR amplification;
m: DNA Marker DL 2000; 1: PCR products; 2: negative control;
figure 2 is the tertiary structure of novel catinterferon omega;
FIG. 3 shows the result of identifying recombinant expression vector pCold-TF-omega;
A. enzyme digestion identification result, M: DNA Marker 8000; 1: the result of the Kpn I-BamH I double enzyme digestion identification of the recombinant plasmid pCold-TF-omega; 2: negative control, b.pcr assay result, M: DNA Marker 8000; 1: PCR amplification result of the recombinant plasmid pCold-TF-omega; 2: negative control;
FIG. 4 is the induced expression profile of feline interferon omega;
A. soluble expression of recombinant protein: m. protein standard molecular weight; 1-5, inducing the recombinant bacteria pCold-TF-omega/BL 21; 6. the non-induced recombinant bacterium pCold-TF-omega/BL 21; 7. the result of induction of the empty vector bacterium pCold-TF/BL 21; B. his-tag affinity purification results of feline interferon omega: m. protein standard molecular weight; 1. the invention relates to a cat interferon omega protein.
Figure 5 is a graph of the potent antiviral activity of feline interferon omega of the invention;
figure 6 is the potent antiviral activity of feline interferon alpha;
figure 7 is the potent antiviral activity of feline interferon omega 2;
figure 8 is the potent antiviral activity of feline interferon omega 9.
Detailed Description
The present invention is further illustrated by the following examples, which are not intended to limit the scope of the invention in any way.
Example 1 acquisition of novel catinterferon omega
1. Primer design and sequence analysis
According to a cat interferon omega gene sequence published in GenBank, gene sequence alignment is carried out through DNAMAN, a pair of degenerate primers are designed by using Oligo6 to amplify the full length of the cat interferon omega gene, and BamH I and Kpn I restriction enzyme sites (used for constructing a recombinant expression vector for expressing cat interferon) are introduced at the 5 'end and the 3' end of the primers. The primer sequences are shown in Table 1, and the primers were synthesized by Jilin province Cumei Biotech Co., Ltd.
TABLE 1 primer sequences
2. Extraction of feline genomic RNA
The invention adopts a method of virus stimulation (feline enterocoronavirus) and interferon inducer stimulation (poly I: C) to stimulate pet cats so as to induce the expression of feline interferon genes. The specific operation is as follows:
cat kidney cells F81 were seeded in 96-well cell plates and incubated at 37 ℃ with 5% CO2Culturing in an incubator until cells grow into a monolayer, inoculating feline enteric coronavirus, adsorbing at 37 deg.C for 1 hr, adding a maintenance solution, placing in an incubator at 37 deg.C and 5% CO2, culturing, observing cytopathic condition day by day, freezing and thawing cells until cytopathic Condition (CPE) reaches above 85%, centrifuging at 3000r/min for 10min to obtain virus solution, and determining virus TCID50. Get 100TCID50The virus solution is mixed with 0.5mg of poly I: C, and injected into pet cats for 3 days and 1 time per day. On day 5, euthanizing the cat, obtaining the spleen of the cat under an aseptic condition, cutting the spleen into pieces, freezing and grinding the pieces into powder by liquid nitrogen, and transferring the powder into a centrifuge tube; adding 2mL Trizol to lyse the cells, sucking 800. mu.L of lysed cell lysate and placing it in a 1.5mL centrifuge tube, adding 1/5 volumes of pre-cooled chloroform, shaking and mixingHomogenizing for 15s, centrifuging at 12000rpm and 4 deg.C for 15 min; collecting supernatant, adding equal volume of precooled isopropanol, acting at 4 deg.C for 10min, centrifuging at 12000rpm and 4 deg.C for 10 min; discarding the supernatant, and centrifuging for 10min at 4 ℃ by precooling 75% ethanol at 12000 rpm; the supernatant was discarded, dried at room temperature, and 30. mu.L of deionized water was added to dissolve the precipitate, thereby obtaining total RNA. Then, the extracted total RNA was reverse-transcribed into cDNA using Superscript reverse transcriptase reagent kit, and stored in a freezer at-80 ℃ for use.
3. PCR amplification
And (3) amplifying the cat interferon gene by using the obtained cDNA as a template.
The PCR reaction system is as follows: 10 XPCR Buffer 2.5. mu. L, dNTPs 3. mu.L, Taq DNA polymerase 0.5. mu.L, Primer pair (Primer-F and Primer-R, 10uM) 2. mu. L, cDNA template 5. mu. L, ddH2O 12. mu.L.
And (3) PCR reaction conditions: 5min at 95 ℃; 35 cycles of 95 ℃ for 30s, 55 ℃ for 45s and 72 ℃ for 30 s; final extension at 72 ℃ for 10 min.
The PCR product was detected by electrophoresis on a 1% agarose gel, and the results are shown in FIG. 1. The PCR product is recovered by a DNA gel recovery kit, sequenced and subjected to BLAST comparison of the sequence, the result is shown in Table 2, the gene sequence obtained by PCR amplification has higher homology with the published gene sequence of the feline interferon omega, belongs to a new member of the feline interferon omega, the nucleotide sequence of the gene sequence is shown as SEQ ID No.1, and the coded amino acid sequence is shown as SEQ ID No. 2.
TABLE 2 alignment of the gene sequences of the invention with known feline interferon gene homology BLAST
4. Interferon tertiary structure prediction
The protein tertiary structure of the interferon of the present invention was predicted using SWISS-MODEL software, and the prediction results are shown in FIG. 2.
Example 2 Mass expression of novel Cat Interferon omega
1. Construction of recombinant expression vector pCold-TF-omega
The expression vector pCold-TF and the PCR product of the novel cat interferon omega obtained in the embodiment 1 are subjected to double enzyme digestion treatment by restriction enzymes Kpn I and BamH I, a DNA gel recovery kit is adopted to recover a target gene fragment, and then the PCR product of the novel cat interferon omega coding gene is connected into the expression vector pCold-TF by T4 ligase to construct a recombinant expression vector pCold-TF-omega.
2. Construction of recombinant bacterium pCold-TF-omega/BL 21
The recombinant expression vector is transformed into BL21 competent cells, the competent cells are spread on an LB agar plate containing ampicillin resistance for culture, positive recombinant bacteria are selected and identified by adopting an enzyme cutting method (the result is shown in figure 3A) and a PCR method (the result is shown in figure 3B), and the recombinant bacteria are named as pCold-TF-omega/BL 21.
3. Inducible expression
The recombinant bacteria pCold-TF-omega/BL 21 were activated by plating overnight, and a single colony was inoculated into 5mL of LB liquid medium containing 100. mu.g/mL ampicillin and cultured overnight with shaking at 37 ℃. Transferring the new culture broth into 20mL LB liquid medium containing benzyl resistance at a ratio of 1:10, and culturing at 37 deg.C to OD600At about 0.5, IPTG was added to a final concentration of 1mmol/L and induction was carried out at 37 ℃ for 6 h. 2mL of the induced recombinant bacterial liquid is taken, centrifuged at 12000rpm for 5min, the supernatant is discarded, 400 mu L of PBS is added to resuspend the thallus and is subjected to ultrasonic treatment, then 100 mu L of 5 xSDS sample lysate is added, boiled water bath is carried out for 10min, centrifuged at 12000rpm for 10min, the supernatant is taken and is subjected to 12% SDS-PAGE analysis, and the result shows that the recombinant protein obtains prokaryotic soluble expression (see figure 4A). And (3) subjecting the recombinant fusion protein (the tag protein and the target protein) to His-tag affinity purification, and then subjecting the recombinant fusion protein to HRV 3C protease treatment and His-tag affinity purification to finally obtain the cat interferon omega protein (shown in figure 4B).
Example 3 determination of antiviral Activity of novel Cat Interferon omega
The antiviral activity of the novel feline interferon omega obtained by the invention is measured by taking feline enterocoronavirus and feline parvovirus as model viruses and adopting a microcytopathic inhibition method. The specific operation is as follows:
cat kidney cells F81 were seeded in 96-well cell plates and incubated at 37 ℃ with 5% CO2Culturing in an incubator until cell monolayer is reached, and respectively adding 2 times of dilutionThe novel cat interferon omega of the invention acts for 16h, and then 100TCID is added into each hole50The virus liquid of (2) is simultaneously provided with a negative control group and known cat alpha, omega 2 and omega 9 interferon positive control groups, and the cytopathic condition is observed after 24 hours.
TABLE 3 comparison of the antiviral Activity of Interferon
Note: + indicates no cytopathy (i.e. antiviral activity) and-indicates cytopathy (i.e. no antiviral activity).
The results of the antiviral activity test are shown in table 3 and fig. 5-8, and it can be seen from the results that the novel feline interferon omega of the present invention has good antiviral activity, the effective antiviral concentration is 0.70mg/mL (shown in fig. 5), and the activity is superior to the activity of the known feline interferon alpha (0.93mg/mL) (shown in fig. 6), the known feline interferon omega 2 (0.87mg/mL) (shown in fig. 7) and the known feline interferon omega 9 (0.91mg/mL) (shown in fig. 8), and the activity shows good application potential.
Sequence listing
<110> northeast university of agriculture
<120> feline interferon omega, coding gene thereof and application thereof in antiviral aspect
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 588
<212> DNA
<213> cattus
<400> 1
atggctctgc tgctgcctct attgactgct ttggctttgt tgacttgtag accaggtggt 60
tccttgggat gcgccctgcc aggttatcac gctcaggttt ccagagacaa cttggttttg 120
ttgggtcaga tgagaagatt gtccccattc ttgggtttga gagccaggaa ggacttcaga 180
ttccctagag agatgttgga gggtggtcaa ctgcgtgaag ctcaagctgc tgctgccgtg 240
ttgagagagt tgttgcagca aaccttcaac ctgttgcata ctgagagatc ctccgctgct 300
tggtccccag atccattgca cggtttgaga tctggtttgc atcgtcaatt ggaggctttg 360
gacgcctgct tgttgcaggc taccggtgag ggtgaaagag ctccaggtat gcacggtcca 420
gctttggcca tcaagcgtta cttccaggcc attagagtct acctggaaga tgagggttac 480
tctgactgcg cttgggagat cgttagacca gaaatgatga gagctttgtc ttcttctgct 540
actttgcaag actctttggc tattaaggat ggagacctgg cgtcatct 588
<210> 2
<211> 196
<212> PRT
<213> cattus
<400> 2
Met Ala Leu Leu Leu Pro Leu Leu Thr Ala Leu Ala Leu Leu Thr Cys
1 5 10 15
Arg Pro Gly Gly Ser Leu Gly Cys Ala Leu Pro Gly Tyr His Ala Gln
20 25 30
Val Ser Arg Asp Asn Leu Val Leu Leu Gly Gln Met Arg Arg Leu Ser
35 40 45
Pro Phe Leu Gly Leu Arg Ala Arg Lys Asp Phe Arg Phe Pro Arg Glu
50 55 60
Met Leu Glu Gly Gly Gln Leu Arg Glu Ala Gln Ala Ala Ala Ala Val
65 70 75 80
Leu Arg Glu Leu Leu Gln Gln Thr Phe Asn Leu Leu His Thr Glu Arg
85 90 95
Ser Ser Ala Ala Trp Ser Pro Asp Pro Leu His Gly Leu Arg Ser Gly
100 105 110
Leu His Arg Gln Leu Glu Ala Leu Asp Ala Cys Leu Leu Gln Ala Thr
115 120 125
Gly Glu Gly Glu Arg Ala Pro Gly Met His Gly Pro Ala Leu Ala Ile
130 135 140
Lys Arg Tyr Phe Gln Ala Ile Arg Val Tyr Leu Glu Asp Glu Gly Tyr
145 150 155 160
Ser Asp Cys Ala Trp Glu Ile Val Arg Pro Glu Met Met Arg Ala Leu
165 170 175
Ser Ser Ser Ala Thr Leu Gln Asp Ser Leu Ala Ile Lys Asp Gly Asp
180 185 190
Leu Ala Ser Ser
195
Claims (9)
1. The cat interferon omega is characterized in that the amino acid sequence of the cat interferon omega is shown as SEQ ID No. 2.
2. A nucleotide sequence encoding the feline interferon omega of claim 1.
3. The nucleotide sequence of claim 2, wherein the nucleotide sequence is set forth in SEQ ID No. 1.
4. A recombinant expression vector comprising the nucleotide sequence of claim 2 or 3.
5. A host cell comprising the recombinant expression vector of claim 4.
6. The use of feline interferon omega of claim 1 in the preparation of an antiviral medicament for treating or preventing a viral infectious disease in a feline.
7. The use of claim 6, wherein the virus comprises feline enterocoronavirus and feline parvovirus.
8. A method of making the feline interferon omega of claim 1, comprising the steps of:
(1) obtaining a nucleotide sequence encoding the feline interferon omega of claim 1, and ligating Kpn I and BamH I cleavage sites at both ends of the sequence;
(2) construction of recombinant expression vector pCold-TF-omega
Respectively carrying out double enzyme digestion treatment on an expression vector pCold-TF and the sequence obtained in the step (1) by using restriction enzymes Kpn I and BamH I, recovering a target gene fragment by using a DNA gel recovery kit, and further connecting the sequence obtained in the step (1) into the expression vector pCold-TF by using T4 ligase to construct a recombinant expression vector named pCold-TF-omega;
(3) construction of recombinant bacterium pCold-TF-omega/BL 21
Transforming BL21 competent cells by using the recombinant expression vector pCold-TF-omega, coating the competent cells on an LB agar plate containing ampicillin resistance for culture, and selecting a positive recombinant bacterium named pCold-TF-omega/BL 21;
(4) inducible expression
Overnight plating and activating recombinant bacteria pCold-TF-omega/BL 21, selecting a single colony, inoculating the single colony in an LB liquid culture medium containing 100 mu g/ml ampicillin, and performing shake culture at 37 ℃ overnight; transferring the new culture broth into LB liquid culture medium containing ampicillin resistance according to the volume ratio of 1:10, and culturing at 37 deg.C to OD600When the concentration is 0.4-0.6, adding IPTG with the final concentration of 1mmol/L, and inducing for 6h at 37 ℃; get and induceCentrifuging the recombinant bacterial liquid, discarding the supernatant, adding PBS (phosphate buffer solution) to resuspend the thallus, carrying out ultrasonic treatment, then adding 5 xSDS (sodium dodecyl sulfate) sample lysate, carrying out boiling water bath for 10min, centrifuging, taking the supernatant, carrying out His-tag affinity purification on the recombinant fusion protein, carrying out HRV 3C protease treatment and His-tag affinity purification, and finally obtaining the feline interferon omega.
9. The method of claim 8, wherein the nucleotide sequence encoding the feline interferon omega of claim 1 is set forth in SEQ ID No. 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811125211.2A CN109206501B (en) | 2018-09-26 | 2018-09-26 | Cat interferon omega, coding gene thereof and application of cat interferon omega in antiviral aspect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811125211.2A CN109206501B (en) | 2018-09-26 | 2018-09-26 | Cat interferon omega, coding gene thereof and application of cat interferon omega in antiviral aspect |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109206501A CN109206501A (en) | 2019-01-15 |
CN109206501B true CN109206501B (en) | 2022-03-04 |
Family
ID=64981572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811125211.2A Expired - Fee Related CN109206501B (en) | 2018-09-26 | 2018-09-26 | Cat interferon omega, coding gene thereof and application of cat interferon omega in antiviral aspect |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109206501B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113461826A (en) * | 2020-03-31 | 2021-10-01 | 成都彤琦恩生物科技有限公司 | Application of signal peptide in recombinant porcine interferon and thymosin fusion protein expression system |
CN112695053B (en) * | 2021-02-05 | 2022-03-29 | 华中农业大学 | Preparation method of recombinant cat interferon |
CN113430220A (en) * | 2021-08-17 | 2021-09-24 | 江苏恒丰强生物技术有限公司 | Synthesis method, construction method and application of genetic engineering bacteria for expressing soluble feline omega interferon |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2019803C (en) * | 1989-06-29 | 2000-04-25 | Akira Yanai | Feline interferon and process for production thereof |
JP2003339261A (en) * | 2002-05-29 | 2003-12-02 | Toray Ind Inc | Plant for expressing cytokine derived from cat and method for producing cytokine derived from cat |
CN1730491A (en) * | 2005-08-09 | 2006-02-08 | 中国科学院微生物研究所 | Cat omega interferon and encoding gene thereof and application |
WO2010016525A1 (en) * | 2008-08-05 | 2010-02-11 | 東レ株式会社 | Immunity inducer |
CN104788554A (en) * | 2015-04-23 | 2015-07-22 | 中国农业科学院生物技术研究所 | Cat omega interferon mutant as well as preparation method and application thereof |
CN107569516A (en) * | 2017-08-16 | 2018-01-12 | 北京京蒙细胞生物科技股份有限公司 | A kind of medicine for controlling cat distemper heat and its preparation method and application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
-
2018
- 2018-09-26 CN CN201811125211.2A patent/CN109206501B/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2019803C (en) * | 1989-06-29 | 2000-04-25 | Akira Yanai | Feline interferon and process for production thereof |
JP2003339261A (en) * | 2002-05-29 | 2003-12-02 | Toray Ind Inc | Plant for expressing cytokine derived from cat and method for producing cytokine derived from cat |
CN1730491A (en) * | 2005-08-09 | 2006-02-08 | 中国科学院微生物研究所 | Cat omega interferon and encoding gene thereof and application |
WO2010016525A1 (en) * | 2008-08-05 | 2010-02-11 | 東レ株式会社 | Immunity inducer |
CN104788554A (en) * | 2015-04-23 | 2015-07-22 | 中国农业科学院生物技术研究所 | Cat omega interferon mutant as well as preparation method and application thereof |
CN108276486A (en) * | 2015-04-23 | 2018-07-13 | 中国农业科学院生物技术研究所 | 2 interferon mutants of cat ω and its preparation method and application |
CN108314724A (en) * | 2015-04-23 | 2018-07-24 | 中国农业科学院生物技术研究所 | 11 interferon mutants of cat ω and its preparation method and application |
CN107569516A (en) * | 2017-08-16 | 2018-01-12 | 北京京蒙细胞生物科技股份有限公司 | A kind of medicine for controlling cat distemper heat and its preparation method and application |
Non-Patent Citations (9)
Also Published As
Publication number | Publication date |
---|---|
CN109206501A (en) | 2019-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109206502B (en) | Cat interferon omega, preparation method thereof and application thereof in antivirus | |
CN109206501B (en) | Cat interferon omega, coding gene thereof and application of cat interferon omega in antiviral aspect | |
CN106282216B (en) | A kind of preparation method of recombinant long-acting chicken interferon α | |
Sun et al. | Interleukin-8 of Cynoglossus semilaevis is a chemoattractant with immunoregulatory property | |
Hu et al. | CXCL8 of Scophthalmus maximus: Expression, biological activity and immunoregulatory effect | |
CN111944837B (en) | Expression vector for expressing COVID-19 antigen and construction method of genetically engineered lactobacillus oral vaccine | |
CN108424915A (en) | The preparation method of 2 recombinant proteins of dog interferon-α | |
CN108840947A (en) | Bovine albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of ox long-acting interferon | |
CN106939042B (en) | Porcine alpha interferon and application thereof | |
CN109627316B (en) | Grass carp IFN-gamma 2 gene, recombinant protein coded by same and application of gene | |
CN109200271B (en) | Protein and application thereof in regulating and controlling macrophage immune function | |
CN108264548B (en) | Mandarin fish gamma interferon related factor, recombinant protein and application thereof | |
CN108840946A (en) | Dog albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of dog long-acting interferon | |
CN117224669A (en) | Application of African swine fever virus MGF360-21R protein as immunity inducer or adjuvant | |
CN1611604A (en) | Swine alpha-interferon gene synthesis, expression vector establishment and product preparing method | |
CN113717268B (en) | Application of koi serum amyloid A5 or encoding gene thereof in regulation and control of koi antipathogenic bacterial infection | |
CN108822220A (en) | Sheep albumin-interferon-tau-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of sheep long-acting interferon | |
CN108840945A (en) | Pig albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a boar long-acting interferon | |
CN109369794B (en) | Protein with function of regulating and controlling macrophage immune function activity | |
CN110437328B (en) | Porcine interferon alpha mutant YNS and preparation method and application thereof | |
CN108048475B (en) | Sinonovacula constricta I type lysozyme-2 gene, encoding protein and construction method of recombinant sinonovacula constricta I type lysozyme-2 gene engineering bacteria | |
CN108251440B (en) | Sinonovacula constricta lysozyme gene, coding protein and construction method and application of recombinant sinonovacula constricta lysozyme gene engineering bacteria | |
CN104531691A (en) | Primers for obtaining genes of bovine interferon alpha and preparation method for recombinant bovine interferon alpha | |
CN108864300A (en) | Chicken Albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a breeder long-acting interferon | |
CN113880932B (en) | Application of koi Ladderlectin protein or encoding gene thereof in regulation and control of koi anti-pathogenic bacterial infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220304 |